Associated tags: DSM-IV codes, FDA, Quality of life, TMS, Tic disorder, Mental health, MDD, Transcranial magnetic stimulation, Neuroscience, Depression, Patient, STIM, Pharmaceutical industry, Neuronetics
Locations: UNITED STATES, TX, FL, NJ, NM, DC, WI, NC, IL, AZ, MI, WY, TN, KS, MO, SC, MALVERN, PA, US, EASTERN
FDA,
Social media,
Food,
Neuronetics,
Partnership,
Depression,
Adolescence,
Webcast,
Knowledge,
DSM-IV codes,
Patient,
Transcranial magnetic stimulation,
Health,
Telephone,
Food and Drug Administration,
MDD,
Transformation,
Ageing,
TMS In the first quarter of 2024, U.S. treatment session revenue per active site was $11,300 compared to $9,700 in the first quarter of 2023.
Key Points:
- In the first quarter of 2024, U.S. treatment session revenue per active site was $11,300 compared to $9,700 in the first quarter of 2023.
- Operating expenses during the first quarter of 2024 were $19.9 million, a decrease of $1.4 million, or 7%, compared to $21.3 million in the first quarter of 2023.
- Net loss for the first quarter of 2024 was $(7.9) million, or $(0.27) per share, as compared to $(10.5) million, or $(0.38) per share, in the first quarter of 2023.
- EBITDA for the first quarter of 2024 was $(6.3) million as compared to the first quarter of 2023 EBITDA of $(9.4) million.
MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees.
Key Points:
- MALVERN, Pa., May 03, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 55,650 shares of the Company’s common stock (RSUs) to thirteen new non-executive employees.
- In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
- Each of the RSU grants vests ratably in equal installments on the first, second, third and fourth anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date.
- The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024.
Key Points:
- MALVERN, Pa., April 23, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2024 financial and operating results prior to market open on Tuesday, May 7th, 2024.
- The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
- The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/i3t5h9gs .
- To listen to the conference call on your telephone, participants may register for the call here .
Retrieved on:
Wednesday, April 10, 2024
STIM,
FDA,
Publication,
Radiology,
Clinical research,
Columbia University,
Research,
Depression,
Development,
DSM-IV codes,
Senior,
Patient,
Transcranial magnetic stimulation,
Marketing,
Quality of life,
MDD,
TMS This analysis concludes that while early symptom improvement in major depressive disorder (MDD) is strongly predictive of response at the completion of transcranial magnetic stimulation (TMS) treatment (36 sessions), lack of early improvement does not predict final treatment outcome.
Key Points:
- This analysis concludes that while early symptom improvement in major depressive disorder (MDD) is strongly predictive of response at the completion of transcranial magnetic stimulation (TMS) treatment (36 sessions), lack of early improvement does not predict final treatment outcome.
- This paper builds upon prior publications utilizing data from our proprietary TrakStar database, which showed a correlation between treatment sessions completed and positive clinical outcomes.
- Treating to completion of 36 NeuroStar sessions offers patients the greatest potential to benefit from NeuroStar TMS treatment."
- In October 2023, additional clinical findings published in Brain Stimulation revealed a strong association between the number of treatment sessions completed and improved depression outcomes.
Retrieved on:
Wednesday, March 27, 2024
MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees.
Key Points:
- MALVERN, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards of Restricted Stock Units representing a total of 135,000 shares of the Company’s common stock (RSUs) to eleven new non-executive employees.
- In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as material inducements to their respective employment with the Company.
- Each of the RSU grants vests ratably in equal installments on the first, second, third and fourth anniversaries of the grant date, subject to the recipient’s continued service with the Company through the applicable vesting date.
- The RSUs are subject to the terms of the Neuronetics 2020 Inducement Plan.
Depression,
Prevalence,
Data analysis,
MDD,
COVID-19,
Patient,
Education,
Ageing,
Transcranial magnetic stimulation,
TMS,
DSM-IV codes,
Quality of life,
Adolescence,
Safety,
Marketing,
STIM,
FDA,
Parent,
Food,
Pharmaceutical industry NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.
Key Points:
- NeuroStar is the first and only transcranial magnetic stimulation (TMS) treatment FDA-cleared for this age group, making it the fourth FDA-cleared indication for NeuroStar.
- "The prevalence of depression in adolescents and young adults has been accelerating since the COVID-19 pandemic.
- "NeuroStar’s TMS therapy now offers a promising first-line treatment for adolescents, backed by real-world data and impressive response rates consistent with response rates for adults.
- This advancement has the potential to set a new treatment paradigm for how we address depression in our youth."
TMS,
Mental health,
TCN,
Transcranial magnetic stimulation,
TRD,
Marketing,
FDA,
Quality of life,
Hope,
Standard of care,
STIM,
Depression,
Patient,
DSM-IV codes,
Mental,
MDD,
Partnership MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers.
Key Points:
- MALVERN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced an expanded commercial partnership with Transformations Care Network ("TCN"), one of the nation's largest mental health care providers.
- Under the new agreement, Neuronetics will be the exclusive supplier of new transcranial magnetic stimulation (TMS) equipment to TCN, increasing its NeuroStar TMS footprint and availability to patients.
- "Transformations Care Network's alliance with NeuroStar is more than a milestone; it is a tangible manifestation of our vision to integrate the most advanced treatments in our suite of services," said Brian Wheelan, Chief Executive Officer at Transformations Care Network.
- To learn more about Transformations Care Network, visit www.transformationsnetwork.com .
Social media,
TMS,
Transcranial magnetic stimulation,
Telephone,
Marketing,
SSM Health,
Webcast,
Health,
Neuronetics,
Patient,
Policy,
Ferdinand Magellan,
Knowledge,
Psychotherapy For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.
Key Points:
- For the period ended December 31, 2023 and 2022, the Company shipped 205 and 213 systems, respectively.
- Gross margin for the full year 2023 were 72.5%, a decrease of approximately 380 basis points from the full year 2022 gross margin of 76.3%.
- Operating expenses during the full year 2023 was $82.3 million, a decrease of $2.5 million, or 2.9% compared to $84.8 million in the full year 2022.
- See the accompanying financial table that reconciles EBITDA, which is a non-GAAP financial measure, to net loss.
Retrieved on:
Tuesday, February 20, 2024
The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
Key Points:
- The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.
- The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/7cha7jae.
- To listen to the conference call on your telephone, participants may register for the call here .
- While it is not required, it is recommended you join 10 minutes prior to the event start.
Retrieved on:
Monday, February 12, 2024
The update introduces features to streamline the way practices track and document status for their potential and current patients.
Key Points:
- The update introduces features to streamline the way practices track and document status for their potential and current patients.
- "It's essential for healthcare providers to have the most recent technology that supports them in continuously improving patient care processes," stated Cory Anderson, SVP of R&D and Clinical.
- All the features are designed to save practices time, allowing them to focus more on direct patient care rather than administrative tasks.
- Another notable feature in this TrakStar release is a more robust Benefits Investigation report that provides practices with estimated patient financial responsibility prior to a patient beginning treatment.
